Register for our free email digests:
Jessica Merrill
Latest From Jessica Merrill
Pfizer's COVID-19 Vaccine Commercialization Plan Includes DTC Campaign
The company is planning a direct-to-consumer education campaign to inform the public about the importance of vaccination.
A Slimmed-Down Pfizer Sets A New R&D Goal: 25 Launches By 2025
The company showcased its pipeline in a two-day virtual meeting, trying to convince investors the long-term potential is undervalued.
Twice As Nice: Seattle Genetics, Merck & Co. Partner On Two Cancer Drugs
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
Virtual JPM: The Industry's Big Annual Party Will Take Place Without The Party
The J.P. Morgan Healthcare conference – where the biopharma industry usually kicks off the year – will be held virtually in 2021, because of COVID-19.
Intra-Cellular's Lumateperone Poised For New Bipolar Depression Opportunity
The company is on track to file an sNDA for lumateperone after a Phase III clinical trial met the primary endpoint in bipolar I and II disorder.
GSK's Trelegy Ellipta Is First Triple Combination Approved For Asthma In the US
Trelegy, already approved for COPD, will be targeted to the roughly one-third of asthmatics not controlled on maintenance therapy.